A retrospective cohort study of 474 BRCA1/2 carriers with high-grade serous ovarian cancer also revealed a significantly higher average age at diagnosis for BRCA2 versus BRCA1 mutation carriers (58.4 years vs. 53.3 years, P = .001) (6, 32). The gene discussed is BRCA2; the disease is ovarian serous adenocarcinoma.